SCHEMBL5843795

SCHEMBL5843795

O=C(Nc1ccc(-c2ccccc2)cc1)C1CC(=O)N(C2Cc3ccccc3C2)C1

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.65
SMN1; SMN2 Q16637 3/20 0.65
TDP1 Q9NUW8 2/20 0.50
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
CA4 P22748 1/20 0.50
CA6 P23280 1/20 0.50
CA7 P43166 1/20 0.50
CA9 Q16790 1/20 0.50
CA13 Q8N1Q1 1/20 0.50
CA5B Q9Y2D0 1/20 0.50
ROCK2 O75116 1/20 0.49
ROCK1 Q13464 1/20 0.49
MAPT P10636 1/20 0.49
LMNA P02545 1/20 0.49
HTT P42858 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5843865 0.91 ALDH1A1 (0.62) ALDH1A1SMN1; SMN2TDP1
SCHEMBL5843404 0.90 ALDH1A1 (0.68) ALDH1A1SMN1; SMN2TDP1CA12CA1
SCHEMBL5842752 0.85 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2TDP1MAPTLMNA
SCHEMBL5841897 0.85 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2MAPTLMNAHTT
SCHEMBL5844508 0.82 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2CA12CA1CA2
SCHEMBL5841595 0.82 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2MAPTLMNAHTT
SCHEMBL5843238 0.82 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2ROCK2ROCK1LMNA
SCHEMBL5842760 0.82 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2MAPT
SCHEMBL5841930 0.82 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2LMNAHTT
SCHEMBL5842367 0.82 ALDH1A1 (0.54) ALDH1A1SMN1; SMN2TDP1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7067549-B2 Pyrrolidone carboxamides ACTELION PHARMACEUTICALS AG (CH) 2006-06-27 US disclosed
US-20050192292-A1 Pyrrolidone carboxamides ACTELION PHARMACEUTICALS AG (CH) 2005-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050192292-A1 Pyrrolidone carboxamides NPY1R, NPY5R, NPY2R ALDH1A1 3034/4885SMN1; SMN2 3678/4885TDP1 3359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.